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Abstract
Background: Alzheimer’s disease (AD) represents the most common form of dementia in elder populations with
approximately 30 million cases worldwide. Genome wide genotyping and sequencing studies have identified many
genetic variants associated with late-onset Alzheimer’s disease (LOAD). While most of these variants are associated
with increased risk of developing LOAD, only limited number of reports focused on variants that are protective
against the disease.
Methods: Here we applied a novel approach to uncover protective alleles against AD by analyzing genetic and
phenotypic data in Mount Sinai Biobank and Electronic Medical Record (EMR) databases.
Results: We discovered a likely loss-of-function small deletion variant in the caspase 7 (CASP7) gene associated
with significantly reduced incidence of LOAD in carriers of the high-risk APOE ε4 allele. Further investigation of four
independent cohorts of European ancestry revealed the protective effect of the CASP7 variant against AD is most
significant in homozygous APOE ε4 allele carriers. Meta analysis of multiple datasets shows overall odds ratio = 0.45
(p = 0.004). Analysis of RNA sequencing derived gene expression data indicated the variant correlates with reduced
caspase 7 expression in multiple brain tissues we examined.
Conclusions: Taken together, these results are consistent with the notion that caspase 7 plays a key role in
microglial activation driving neuro-degeneration during AD pathogenesis, and may explain the underlying genetic
mechanisms that anti-inflammatory interventions in AD show greater benefit in APOE ε4 carriers than non-carriers.
Our findings inform potential novel therapeutic opportunities for AD and warrant further investigations.
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Background
The prevalence of dementia in the Western population over
age of 60 has been estimated to exceed 5 %. Alzheimer’s
disease (AD) is the leading cause of dementia accounting
for approximately 30 million cases worldwide [1, 2]. The in-
cidence and prevalence of AD is age dependent, doubling
every 5 years after age 65 [3]. As the proportion of popula-
tion over 60 years of age continues to rise, the number of
individuals developing AD will also increase, presenting a
major health issue worldwide. Pathologically, AD is defined
by extensive neuronal loss and accumulation of extracellu-
lar amyloid plaques formed by aggregation of β-amyloid
(Aβ) peptides and intracellular neurofibrillary tangles com-
posed of hyper-phosphorylated tau proteins [4].
AD has a strong genetic component. It has been gener-
ally recognized that there are two major categories of AD,
familial early-onset AD (EOAD) and sporadic late-onset
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AD (LOAD). EOAD represents less than 1 % of all AD
cases and they are characterized by early-onset, often be-
fore age 60, and Mendelian inheritance occurring mostly
in an autosomal dominant manner. Linkage analysis of
EOAD families in the 80’s and early 90’s led to the discov-
eries of fully penetrant disease causing mutations in APP
encoding β-amyloid precursor protein, PSEN1 and PSEN2
encoding components of the γ-secretase complex, prese-
nilin 1 and presenilin 2 respectively [5]. In amyloidogenic
pathway, APP, a transmembrane protein is first cleaved by
a β-secretase, encoded by BACE1 and subsequently by the
γ-secretase complex to form Aβ peptides [6, 7]. Identifica-
tion of disease causing mutations in APP, PSEN1, PSEN2
underscores the pathogenic role of the amyloidogenic
pathway in AD development [8, 9].
Linkage studies, genome-wide association studies
(GWAS), and recent whole exome sequencing (WES)
have identified dozens of risk genes in LOAD [4, 5, 10].
These risk genes have created a broader picture of path-
ways involved in AD pathogenesis. Several pathways
have been highlighted by these genes, including choles-
terol metabolism (APOE, CLU, ABCA7), immune re-
sponse (CR1, CD33, MS4A, TREM2) and endocytosis
(BIN1, PICALM, CD2AP, EPHA1, SORL1) [4]. Among
AD risk genes and variants, APOE is the strongest risk
factor. APOE has three isoforms determined by cysteine-
to-arginine substitutions at amino acid position 112 and
158, corresponding to two SNPs (rs429358 and rs7412 re-
spectively) [11, 12]. The three isoforms are referred as
APOE2 (cys112, cys158), APOE3 (cys112, arg158) and
APOE4 (arg158, arg158) with the corresponding alleles
designated ε2, ε3, and ε4 respectively [13]. APOE ε3 is the
most common isoform with 60-70 % [14] allele frequency.
APOE ε4 allele is associated with increased AD risk in
both familial EOAD and sporadic LOAD, with 2–5 fold
increased risk for heterozygous carriers and 12–15 fold in-
creased risk for homozygous carriers in Caucasian popula-
tions [5, 15]. These risks have been estimated for as a 5.7
fold increase in homozygous and no increased risk in het-
erozygotes in the African American population [16]. In
Hispanics, this risk is estimated to be 2.2 fold in homozy-
gotes with no increased risk in heterozygotes [16]. How-
ever, there is a greater prevalence of Alzheimer’s and other
dementias in African-Americans and Hispanics, suggest-
ing other environmental or genetic factors are at play [17].
Elucidating the functional effects of naturally occur-
ring genetic variants is one of the major challenges in
genetic studies of human diseases [18]. With most of the
genetic studies focused on variants associated with in-
creased AD risks, there are a limited number of reports
discussing variants that render protective effects against
AD. The most notable example is the APP A673T muta-
tion protecting against AD as well as cognitive decline
in the elderly without AD due to 40 % reduction in the
formation of Aβ peptides [19]. Missense variants in sev-
eral other genes associated with lowered risk of AD or
neuronal atrophy, including TREML2 [20], HMGCR
[21], and REST [22], have recently been described. In
this study, we applied a novel approach to discover AD
protective variants by identifying genetic modifiers for AD
risk in APOE high-risk ε4 allele carriers. Genotyping data
of approximately one million markers plus 37 million im-
puted SNPs in Mount Sinai Biobank [23] were analyzed
and a small deletion variant (rs10553596) in the coding re-
gion of caspase 7 gene (CASP7) was found to be signifi-
cantly associated with reduced incidence of AD and
dementia in APOE ε4 carriers. The protective effect of
rs10553596 is observed in four independent LOAD co-
horts. Interestingly, the protective effect of this CASP7
variant appears to be most significant in homozygous
APOE ε4 carriers. At gene expression level, eQTL analysis
indicated that the rs10553596 variant is correlated with
lowered caspase 7 expression. These results provide new
insights into the underlying genetic mechanism of AD as
well as opportunities for novel therapeutic strategies.
Methods
Study participants or study cohorts
We analyzed 6 datasets (Table 1): Mount Sinai Biobank
(~14 K individuals with genotype data), Geisinger Health
System (GHS) MyCode Cohort (9856 unrelated individ-
uals, [24]), GBAD (1588 individuals, http://www.ncbi.nlm.
nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs00021
9.v1.p1), ADNI (2826 individuals, http://adni.loni.usc.edu),
ADSP (10,939 individuals, https://www.niagads.org/adsp/
content/home), and ADGC (6065 individuals, http://
www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?stud
y_id=phs000372.v1.p1). ADSP is a large AD cohort in-
cluding whole genome sequencing data. However, after
downloading all APOE ε4 homozygotes and filtering for a
read count ≥10 for the CASP7 variant, only one control
remained (Table 1), and thus the data was not included in
the meta-analysis.
The Mount Sinai Biobank cohort
Mount Sinai Biobank was established in 2007 in New
York city and is distinguished among most biobanks be-
cause the participants are recruited from highly diverse
communities, with the majority being either Hispanic or
African American [23]. Currently it has collected DNA
samples from more than 30,000 enrolled participants, and
genotyping data has been generated for more than 14,000
patient samples using Illumina OmniExpressExome-8 v1.1
BeadChip that covers approximately one million genetic
markers. Available clinical information for all the partici-
pants such as disease diagnosis, laboratory test results and
medication history were obtained from Mount Sinai elec-
tronic medical record (EMR) databases.
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Genotyping and imputation
SNP genotypes were obtained using Illumina OmniEx
pressExome-8 v1.1 BeadChip (Mt. Sinai), Illumina Infinium
ExomeCore 12v1.0_B (GHS), Affymetrix 500 K array set
(GBAD), Illumina Human610-Quad BeadChip and Illu-
mina HumanOmniExpress BeadChip (https://www.synap-
se.org/#!Synapse:syn2290704/wiki/64710) (ADNI), and Illu
mina Human660W-Quad/HumanOmniExpress (ADGC).
Quality control was performed on all genotype data-
sets prior to imputation. In the Mount Sinai Biobank, in-
dividuals with discordant sex, call rates below 98 %, or
out-lying heterozygosity were removed. SNPs with call
rates below 95 % or with deviation from Hardy-
Weinberg equilibrium (HWE) with p-value < 5e-5 were
also excluded. For the GHS dataset, genotypes were pre-
cleaned and imputed separately as previously described
[25]. Samples with sex mismatches and low call rates
and SNPs with low call rates were removed. For the
GBAD Affymetrix 500 K dataset, the data was pre-QCed
according to the protocol given with the data [26]. The
GBAD data samples with call rates <94 % or gender mis-
matches were removed along with SNPs with HWE p-
value < 5e-7 or call rate <95 % (99 % for MAF <0.05).
For the ADNI dataset, samples with call rates <98 %,
population outliers, and relateds were removed along
with SNPs with HWE p-value < 0.001, minor allele fre-
quency (MAF) < 0.05, or call rate <98 % according the
protocol at http://adni.loni.usc.edu/ and https://www.sy-
napse.org/#!Synapse:syn2290704/wiki/64710. For the
ADGC dataset, data samples with call rates <99 %, gender
mismatches, and individuals with outlying heterozygosity
were removed along with SNPs with HWE p-value < 1e-10,
call rate <98 %, and MAF < 1 %.
All genotype datasets were prephased using SHA-
PEITv2 [27] and imputation was performed with IM-
PUTE2 [28] using the 1000 genomes integrated variant
set as the reference panel. The Mount Sinai Biobank, the
GHS dataset, the ADGC dataset, and the GBAD dataset
were imputed with the phase III haplotype reference
panel, while the ADNI dataset was pre-imputed with
the phase I panel. The imputation info score for the
CASP7 variant rs10553596 was 0.97 in the Mount Sinai
Biobank, and 0.99 in the GBAD, ADGC and GHS
cohorts. For the GHS, GBAD, ADGC, and ADNI
datasets, individuals who had a posterior probability of
less than 0.9 for the most likely genotype were excluded
from the analysis. The CASP7 variant rs10553596 was
imputed in all datasets.
APOE ε4 status
Individuals who have the C/C genotype at rs429358 are
obligate homozygous ε4, and those who harbor the T/T
genotype as rs7412 are obligate non-ε4-carriers. Individ-
uals who were C/C at rs429358 and T/T at rs7412 were
removed from the analysis, as this haplotype is not ob-
served (and it is thus due to genotype error or incorrect
genotype imputation). In the Mt. Sinai Biobank, rs7412
was genotyped while rs429358 was imputed with imput-
ation info of 0.96. Two individuals were excluded from
the analysis due to an inconsistent haplotype. In the
GHS cohort, 2033 individuals were identified as APOE
ε4 carriers (rs7412 was genotyped and rs429358 was im-
puted), of which 812 carry at least 1 allele for CASP7
rs10553596. In the GBAD dataset, rs429358 and rs7412
were genotyped independently. APOE ε4 status and the
CASP7 rs10553596 genotype could be estimated for 1423
of the 1588 individuals. The ADNI dataset included the
number of copies of the APOE ε4 allele (both rs7412
and rs429358 were genotyped). There were 919 indi-
viduals of European descent with APOE ε4 status.
The ADGC dataset provided the two APOE alleles
for each individual.
Table 1 The analyzed datasets in this study
Dataset Samples Cases Controls APOE ε4 Homozygotes….
All Cases Controls
Mt. Sinai All 13,710 238 5325 93 8 85
White 25 1 24
African American 37 3 34
Hispanic/Latino 28 4 24
GHS 7645 287 7358 132 6 126
GBAD 1588 806 782 103 92 11
ADNI 2826 370 569 91 55 28
ADGC 6065 3666 1604 456 419 25
ADSP 10,939 6311 4628 145 96 1
TOTAL 42,773 12,248 20,067 1020 572 (EUR > 60) 190 (EUR > 60)
Some of these numbers may not sum due to various filtering steps. The final case/control totals for the APOE ε4 homozygotes include only those analyzed in the
meta-analysis, and thus do not include the Mt. Sinai or ADSP datasets
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Phenotype determination
Since EOAD occurs in individuals before the age of 60,
we selected individuals older than 60 in all cohorts as
one of the criteria to define LOAD. For both the Mount
Sinai Biobank and GHS EMR data, AD cases were se-
lected using ICD9 billing codes 290, 294, and 331 and all
their subtypes (excluding Reye’s syndrome (331.81) and
alcohol induced dementia (291.2)) from electronic med-
ical records (EMR). Cases were defined as individuals
with first record of AD/dementia diagnoses above age
60. Controls were those over 60 year of age at their last
recorded visit with no records including ICD9 290, 294,
and 331. In the GBAD dataset, LOAD cases and controls
were defined according to the protocol at http://
www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?s-
tudy_id=phs000219.v1.p1. For the ADNI dataset, visits
were recorded for patients in 3 categories: NL (normal),
MCI (mild cognitive impairment), or Dementia. For these
individuals, we used the most severe diagnosis recorded.
Thus, individuals recorded as NL and MCI were consid-
ered controls, and those recorded as Dementia were con-
sidered cases. Only individuals recorded as ‘White’ and
‘Not Hispanic/Latino’ and who were over the age of 60
were analyzed. The ADGC dataset includes individuals
with normal phenotype, AD, or MCI. Individuals classed
as normal/MCI who were over 60 years of age at the last
visit were considered controls, and AD patients with ini-
tial diagnosis after age 60 were considered cases. Only in-
dividuals recorded as “White” and “Not Hispanic/Latino”
who clustered together in PC analysis were analyzed.
Meta analysis
A weighted fixed-effect meta-analysis was performed in the
R package metafor assuming a dominant model for the
CASP7 rs10553596 variant in homozygous APOE ε4 car-
riers, heterozygous ε4 carriers, and non-carriers (adding a
half count to any zero count cells). To test for any possible
population stratification issues within the European co-
horts, we included the first 3 principle components (PCs)
as covariates in a logistic regression model for the APOE ε4
homozygotes for each of the ADNI, ADGC, and GBAD
datasets. The PCs were not statistically significant nor did
they have a notable impact on the estimated odds ratio.
Results and discussion
Identification of genetic variants associated with reduced
AD prevalence in APOE ε4 carriers
We first performed an exploratory analysis in the Mount
Sinai Biobank to find protective alleles for APOE ε4 ho-
mozygotes, who are at high risk for AD. The SNP
rs429358, used to determine APOE ε4 status, is well
known for being difficult to genotype and failed QC on
our array. The imputed genotypes were used to estimate
the APOE ε4 status. Though this variant has overall high
imputation quality, genotype imputation is more difficult
in populations of African ancestry, due to lower linkage
disequilibrium (LD) and higher genetic diversity. If we
were to use a cutoff of genotype posterior probability >
0.9 for the imputed rs429358 SNPs, this would result in
only 29 individuals above age of 60 being assigned as
homozygous APOE ε4 carriers, of which only 2 were di-
agnosed with AD/dementia. We decided to use a loose
threshold of genotype posterior probability (>0.5) for the
APOE SNP rs429358 in order to increase sample size for
a more powerful test of significance. We applied this
threshold to all tested imputed variants. Using ICD9 bill-
ing codes for AD and dementia diagnosis (290, 294 and
331), we had 8 AD/dementia patients and 72 controls.
With a one-sided Fisher’s exact test, we found 12 anno-
tated loss-of-function variants with p-value <0.05 that
were protective for AD/dementia. The top two variants
were in SLC22A24 (a putative ion transporter with un-
known functional relevance to AD) and MUC19 (a gene
known to give false positive associations due to its size).
The third most significant variant was in CASP7,
rs10553596, with an odds ratio of 0.080 and p-value of
0.0062. In this variant, two nucleotides (TT) is deleted
in CASP7 coding region resulted in leucine to serine
change at amino acid position 44 (mRNA accession:
NM_001267057.1; protein accession: NP_001253986.1).
In addition, the TT deletion causes a premature termin-
ation codon downstream at amino acid position 133.
Therefore, it is highly likely this is a loss-of-function vari-
ant. The association of this variant to AD in the APOE ε4
heterozygotes (odds ratio = 0.75, p-value = 0.37) suggests
that the protective effect of rs10553596 against AD in all
APOE ε4 carriers might be present mainly in the APOE
ε4 homozygous population. Rs10553596 is a relatively
common variant in general population, with differing al-
lele frequencies amongst the different 1000 genomes pop-
ulations (Additional file 1: Figure S1).
Next, we reinvestigated rs10553596 with a more strin-
gent threshold for the imputed variants to determine if
an association still holds. To increase the size of the test
group, we performed a case-control analysis of geno-
types between those diagnosed with AD or dementia
and those without among APOE ε4 carriers. Using the
combined posterior probability of homozygous and het-
erozygous rs429358 and the information from the other
genotyped APOE SNP rs7412, we can be fairly confident
whether or not an individual carries at least one copy of
APOE ε4 (we can apply the same rational to the imputed
variant CASP7 variant rs10553596 since we are analyz-
ing a dominant model). With a cutoff for the combined
posterior probability > 0.8, 842 individuals above age of
60 and in the top three largest ethnic groups were iden-
tified as APOE ε4 carriers (Table 2a). As the control
group, 3666 were identified as non-APOE ε4 carriers
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and are above age of 60 (Table 2b). 50 of the 842 APOE
ε4 carriers, and 157 of the 3666 individuals in the con-
trol group were diagnosed with AD or dementia. This
represents an odds ratio of 1.4 fold for AD risk in APOE
ε4 carriers. The result shows that presence of at least
one copy of the rs10553596 alternate allele significantly
lowers the AD risk (odds ratio = 0.56, p = 0.031) in
APOE ε4 carriers (Table 2a). However, when the same
analysis was performed on non-APOE ε4 carriers, no
significant association between rs10553596 and reduced
AD risk was detected (Table 2b) although a trend was
observed. This suggests that rs10553596 is not protect-
ive for AD by its own, but is most likely a modifier for
APOE ε4 alleles on AD risk.
Evaluation of rs10553596 as an AD protective variant
CASP7 encodes a member of the cysteine-aspartic acid
protease (caspase) family. Sequential activation of caspases
plays a central role in the execution-phase of cell apoptosis.
However, the function of caspase 7 is beyond its role in
apoptosis. For example, it has been illustrated that micro-
glia cell activation by inflammatory signals are mediated
through caspase cascade involving caspase 3 and caspase 7,
without triggering apoptosis [29]. Microglial are resident
immune cells in brain acting as the main form of immune
response in central nervous system (CNS). Abnormal
microglial activation causes neurotoxicity and plays a pre-
dominant role in both AD and Parkinson’s disease (PD)
pathogenesis. A recent study has shown that a LD haplo-
type block containing the CASP7 gene is associated with
reduced AD risk in Caribbean Hispanic populations [30].
We then attempted to replicate our findings in five in-
dependent cohorts (Table 1). (1) The GBAD study [26,
31], with French Canadian ancestry, (2) the ADNI study
[32], (3) the GHS MyCode study [24], (4) the ADGC
study [33], and (5) the ADSP study (http://www.ncbi.nlm.-
nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000572.
v1.p1). We assigned each individual into one of the follow-
ing three populations: APOE ε4 homozygotes, APOE ε4
heterozygotes and non-APOE ε4 carriers based on their
APOE genotypes. For the ADSP WGS dataset, after geno-
type calling, we were left with only one APOE ε4 homozy-
gote control, and thus the data was not included in the
meta-analysis. Because these cohorts are of primarily of
European ancestry, one can achieve higher accuracy of
genotype imputation due to longer stretches of LD and
lower genetic diversity. The protective effect of CASP7 vari-
ant rs10553596 was then assessed for individuals with
genotype posterior probability of >0.9 for any genotype in
each of the three sub-populations (APOE ε4 homozygotes,
APOE ε4 heterozygotes and non-APOE ε4 carriers). The
combined meta-analysis p-value (odds ratio) for these four
cohorts was 0.004 (0.45) in homozygous APOE ε4 carriers
(Fig. 1a), indicating a significant protective effect of CASP7
rs1055359. In contrast, this protective effect of the
rs10553596 variant is not observed in APOE ε4 heterozy-
gotes (Fig. 1b) and non-carriers (Fig. 1c).
Interestingly, when we interrogated a centralized
genetic variant repository (DIVAS) we built that in-
cluded genotyping and sequencing data of 150,000 in-
dividuals from multiple disease cohorts [34], we
observed that allele frequency of rs10553596 is signifi-
cantly lower in familial Amyotrophic lateral sclerosis
(ALS) at 5 % in comparison to 19–50 % in healthy
populations (Additional file 1: Figure S2), implicating a
protective effect of this variant against ALS, another
neuro-degenerative disease. The familiar ALS cohort was
downloaded from dbGap with accession phs000101.v4.p1
[35, 36]. Although this observation requires further valid-
ation given rs10553596 is an indel variant and the tech-
nical challenges associated with indel calling, it is
consistent with our findings on the protective effect of
rs10553596 in LOAD. We further assessed the effect of
the rs10553596 variant on CASP7 gene expression
through eQTL analysis. As demonstrated in Table 3, the
alternate allele of rs10553596 is significantly associated
with lowered CASP7 expression in the tissues we exam-
ined, including several brain tissues such as prefrontal cor-
tex, visual cortex and cerebellum. This supports that
rs10553596 is a loss of function variant for CASP7.
African American and Hispanic APOE ε4 carriers have a
lower risk of developing Alzheimer’s or dementia than
European carriers. The allele frequencies of the CASP7
variant rs10553596 differ among the 1000 genomes ethnici-
ties: 34–48 % in African populations, 21–32 % in South
Table 2 Association between CASP7 rs10553596 and AD/
dementia status in APOE ε4 allele carriers (A), and non-APOEε 4
allele carriers (B), stratified by ethnicity in Mount Sinai Biobank
A. Carriers: Overall P-value = 0.031, OR = 0.56 (95 % CI 0.00–0.94)
Ethnicity Phenotype Ref-Ref Alt-* P-value Odds Ratio
European Controls 137 141 0.25 0.49
AD/dementia 6 3
African Controls 68 145 0.19 0.54
AD/dementia 7 8
Hispanic Controls 155 146 0.12 0.56
AD/dementia 17 9
B. Non-Carriers: Overall P-value = 0.060, OR = 0.77 (95 % CI 0.00–1.01)
Ethnicity Phenotype Ref-Ref Alt-* P-value Odds Ratio
European Controls 588 637 0.43 0.83
AD/dementia 10 9
African Control 233 453 0.24 0.74
AD/dementia 14 20
Hispanic Control 867 731 0.17 0.80
AD/dementia 62 42
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Asian populations, 19–29 % in European populations, 21–
28 % in East Asian populations, and 15–28 % in American
populations (Additional file 1: Figure S1). The higher allele
frequency of rs10553596 in African populations might ex-
plain why APOE ε4 African Americans have a lower risk
for Alzheimer’s than Europeans [17]. It is identified in this
study, possibly due to the unique composition of popula-
tion in Mount Sinai Biobank with the majority being either
African American or Hispanic [23], although we were able
to confirm the protective effect of rs10553596 against AD
in four European cohorts. If we plot the frequency of
rs10553596 versus the estimated APOE ε4 frequencies, we
see a general positive correlation (r2 = 0.42), which may re-
flect selective pressure (Additional file 1: Figure S1). We
also realize that diversity of the frequency of this marker
and the varying risks amongst ethnicities may inflate associ-
ation due to subtle population stratification issues. While
this is definitely a possibility in the Mount Sinai Biobank
due to complex admixtures, it is far less likely to be a major
factor in the more homogenous cohorts of European des-
cent (principle component analysis supports this conclu-
sion, see Methods).
The protective effect of rs10553596 against LOAD is only
observed in APOE ε4 homozygote populations (Fig. 1). It
has been well documented that APOE binds to Aβ and in-
fluences the clearance of soluble Aβ and the Aβ aggregation
[4]. However it was unclear whether APOE genotype affects
Aβ-plaque-associated neuro-inflammation until a recent
study demonstrated that in addition to altering morpho-
logical profiles of Aβ deposition, APOE genotype influences
Aβ-induced glial activation in cortex [37], a key step leading
to neuro-inflammation in AD pathogenesis. Given the crit-
ical role of caspase 7 in microglial activation and recent
findings implicating APOE ε4 alleles in modulating neuro-
inflammatory responses in AD development, it is only fit-
ting that the loss-of-function alt allele of rs10553596 in
CASP7 exhibited protective effect against AD in APOE
high-risk ε4 carrier populations. Moreover, the protective
effect of a CASP7 loss-of-function variant against AD
only in APOE ε4 homozygotes may explain the clin-
ical observation that anti-inflammatory interventions
in AD show greater benefit in APOE ε4 carriers as
opposed to non-carriers [38]. As pan-caspase inhibi-
tors have been under development for several auto-
immune diseases [39], our discovery has potentially
significant clinical relevance implicating novel therapeutic
opportunities for AD.
We also recognize the limitations in our study. Lim-
ited sample size is an inherent challenge. Two of the 6
datasets, Mount Sinai Biobank and Geisinger Health
System (GHS) MyCode Cohort, are population-based
data that is not focused on AD. Therefore, the frequency
of APOE ε4 homozygous carriers is equal to the popula-
tion frequency of approximately 1-2 %. Multiple filtering
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Fig. 1 Meta-analysis of association between CASP7 rs10553596 and AD
prevalence in homozygous APOE ε4 carriers (a), heterozygous APOE ε4
carriers (b) and non-carriers (c). Control: individuals not diagnosed with
AD or dementia. Alz/Dem: individuals diagnosed with AD or dementia.
“−” and “+” denote individuals with both ref alleles of rs10553596, or
harboring at least one alt allele of rs10553596, respectively
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steps throughout the analyses (see Methods) further re-
duced the sample size. In addition, there are a significantly
smaller number of AD patients than controls. In contrast,
the 4 AD datasets (GBAD, ADNI, ADGC and ADSP) have
significantly larger number of AD patients than controls
among APOE ε4 homozygous carriers since the APOE ε4
allele is enriched in AD populations. Unbalanced AD vs.
control sample size poses a great challenge to achieve the
level of statistical significance reported in typical GWAS
studies with balanced case vs. control populations of thou-
sands to tens of thousands in sample size. Even with an ori-
ginal sample size of nearly 40,000 individuals, we were left
with <1000 homozygous APOE ε4 individuals for the meta-
analysis (Table 1; Fig. 1). Another limitation is that we
define age 60, a commonly used threshold as a cutoff
for LOAD. It is likely that some of the individuals in
the control population will develop AD as they age.
Therefore, our analyses suggest that the CASP7 variant
rs10553596 protects against AD or simply delays the age
of onset. As more AD genotyping and genomic sequen-
cing data from large consortium become available, we can
define a more stringent age threshold or use age of onset
as a quantitative trait in an AD population to distinguish
these possibilities.
Conclusions
In this study, we analyzed individuals who are APOE ε4
risk allele carriers but are resilient to Alzheimer’s disease,
and discovered a novel AD protective genetic variants
modifying AD risk in APOE ε4 risk allele carriers. Our
analysis of Mount Sinai Biobank cohort led to the identifi-
cation of a likely loss-of-function variant rs10553596 in
CASP7 associated with significantly reduced AD incidence
in elder populations. The protective effect of rs10553596
against AD was observed in four independent cohorts of
European descent with similar odds ratios, and the overall
effect in these cohorts was statistically significant. In
addition, we show rs10553596 is associated in cis with
lowered caspase 7 gene expression. Taken together, these
results are consistent with the notion that caspase 7 plays
a critical role in mediating microglial activation in CNS
that triggers neurotoxicity and AD pathogenesis.
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Table 3 rs10553596-c allele is associated with lower CASP7 gene expression level
Tissue Reporter ID Effective allele eQTL P-value eQTL direction Sample size
Lung 100139172_TGI_at c 2.6e-44 ↓ 1111
Prefrontal cortex 10023817180 c 1.5e-21 ↓ 583
Visual cortex 10023817180 c 4.0e-11 ↓ 409
Cerebellum 10023817180 c 5.7e-12 ↓ 496
Liver 10023817180 c 2.1e-23 ↓ 563
Omental fat 10023817180 c 2.6e-62 ↓ 675
Subcutaneous fat 10023817180 c 1.6e-29 ↓ 611
Expressional QTLs (eQTLs) between rs10553596 and CASP7 expression level were reported in large tissue collections, including lung [40], brain regions [41], liver
[42] and fat tissues [42]. In lung eQTL study, Affymetrix HU133 array was used; and in other eQTL studies, Agilent Human44K1.1 array were employed
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